Treatment Information

Back

Prostate Cancer treatment details. Chemotherapy.

Georges Pompidou European Hospital, Paris, France.

Survival: monthsCountry:France
Toxiciy Grade:4City/State/Province:Paris
Treatments:ChemotherapyHospital:Georges Pompidou European Hospital
Drugs:Journal:Link
Date:May 2005

Description:

Patients: This Phase II study enrolled 130 men, who were randomized into three groups. Group C had 42 men (median age 70) with hormonal-resistant prostate cancer. One patient had metastatic sites in three or more organs, while the rest of the group had metastatic sites in one or two organs. Metastatic sites included bone and lymph node tissue.

Treatment: The treatment for group C involved two chemotherapeutic agents: mitoxantrone and prednisone.

Toxicities: Grade 3-4 toxicities in group C included granulocytopenia (sometimes with fever), anemia, and thrombocytopenia.

Results: For group C, the overall median survival was 13.4 months.

Support: Authors of this study had been employees, consultants, or honorarium recipients for Aventis. Aventis manufactures docetaxel.

Correspondence: Stephane Oudard, MD.



Back